Adalimumab induced-inflammatory myopathy in rheumatoid arthritis

dc.creatorCarlos de Souza, Fernando Henrique
dc.creatorMorais Barros, Thiago Bitar
dc.creatorLevy-Neto, Mauricio
dc.creatorShinjo, Samuel Katsuyuki
dc.date.accessioned2013-10-31T10:46:33Z
dc.date.accessioned2018-07-04T16:06:19Z
dc.date.available2013-10-31T10:46:33Z
dc.date.available2018-07-04T16:06:19Z
dc.date.created2013-10-31T10:46:33Z
dc.date.issued2012
dc.identifierACTA REUMATOLOGICA PORTUGUESA, ALGES, v. 37, n. 2, pp. 180-183, APR-JUN, 2012
dc.identifier0303-464X
dc.identifierhttp://www.producao.usp.br/handle/BDPI/37051
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1631470
dc.description.abstractThe application of immunobiologics for the rheumatoid arthritis treatment may present as a rare complication the development of inflammatory myopathy. Until this moment, there have been described in literature only seven cases of inhibitors of tumor necrosis factor induced-myositis. In this paper, we report the case of the patient with 39 years-old with eight years of arthritis rheumatoid and that due to refractory to various immunosuppressive drugs, the adalimumab was introduced, and evolved to dermatomyositis status.
dc.languagepor
dc.publisherMEDFARMA-EDICOES MEDICAS, LDA
dc.publisherALGES
dc.relationACTA REUMATOLOGICA PORTUGUESA
dc.rightsCopyright MEDFARMA-EDICOES MEDICAS, LDA
dc.rightsopenAccess
dc.subjectADALIMUMAB
dc.subjectDERMATOMYOSITIS
dc.subjectIMMUNOBIOLOGICS
dc.subjectPOLYMYOSITIS
dc.subjectANTISINTETASE SYNDROME
dc.titleAdalimumab induced-inflammatory myopathy in rheumatoid arthritis
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución